Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 15/20 | 0.61 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.34 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.33 |
| ▸ | PLK4 | O00444 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | PDE8A | O60658 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22866579 | 0.93 | NT5E (0.52) | NT5EPDE1C | |
| SCHEMBL22866535 | 0.93 | NT5E (0.52) | NT5EPDE1C | |
| SCHEMBL22843457 | 0.89 | NT5E (0.59) | NT5EGGPS1PDE1CPLK4NTRK1 | |
| SCHEMBL22866583 | 0.88 | NT5E (0.62) | NT5EGGPS1 | |
| SCHEMBL19370338 | 0.87 | NT5E (0.61) | NT5E | |
| SCHEMBL19370331 | 0.87 | NT5E (0.61) | NT5E | |
| SCHEMBL22843571 | 0.87 | NT5E (0.61) | NT5EGGPS1PDE1CPDE8APDE5A | |
| SCHEMBL22843558 | 0.81 | NT5E (0.49) | NT5EPDE1C | |
| SCHEMBL22843594 | 0.81 | NT5E (0.49) | NT5EPDE1C | |
| SCHEMBL19370350 | 0.81 | NT5E (0.63) | NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239912-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20170267710-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267710-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ENTPD5, NT5C2, NT5E | NT5E 3/4885GGPS1 483/4885PDE1C 1413/4885 |
| US-10239912-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ENTPD5, NT5C2, NT5E | NT5E 3/4885GGPS1 493/4885PDE1C 1425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.